AARDEX Group named founding member of CancerX initiative
The public-private partnership announced by The White House is part of the reignited Cancer Moonshot. It is primarily focused on advancing digital innovation to improve equity and reduce ‘financial toxicity’ in cancer care and research.
For many patients, cancer becomes a chronic condition and improving patient dosing is therefore vital to enhance treatment individualization and increase medication adherence.
Although CancerX is a national US-initiative, EU companies like AARDEX bring a ‘special touch’ to the program, including PRECIDOSE, AARDEX’s AI precision dosing technology, which is enhancing medication adherence in daily healthcare settings.
Bernard Vrijens, CEO and scientific lead at AARDEX Group, said: “We need to change how we think about the pathway of cancer treatment. Yes, it is initially about killing the cancer cells but it then becomes a chronic disease for most patients. We need to make sure those patients are receiving appropriate doses and not experiencing too many side effects.”
“Side effects are the number one driver for stopping treatment. Adherence technology can help develop appropriate dosing pathways. It can also help to tackle a growing adherence challenge as more cancer drugs are delivered orally. We are delighted to bring our unique adherence insight and technology to help tackle these challenges head on through the CancerX initiative.”
Santosh Mohan, vice president, digital at Moffitt Cancer Center, added: “Beating cancer demands bold innovation and deliberate collaboration. CancerX is creating a dynamic ecosystem where ideas can flourish, expertise and resources can be shared, and innovative solutions can be rapidly developed and equitably deployed in the fight against cancer.”
“As a co-host, we take immense pride in the diverse and inclusive community of pioneers coming together as members, all driven by a shared commitment to advancing the goals of the Cancer Moonshot. Together, we will advance the frontiers of cancer research and treatment through digital innovation, while striving to reduce the incidence and burden of cancer for all people.”
According to Smit Patel, associate program director at DiMe, multi-stalker collaboration is ‘critical’ to harness the potential of digital innovation in the fight against cancer.
“We’re honored to partner with AARDEX Group to achieve the ambitious goals of CancerX. Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey,” she said.
CancerX is co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe).
